Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel tetramerization domain-containing protein 1 (**KCTD1**) is a member of the KCTD protein family, which share structural similarity to the tetramerization (T1/BTB) domain of voltage-gated potassium channels but do not function as ion channels themselves[1][3][6]. KCTD1 contains a conserved N-terminal BTB (POZ) domain that mediates protein-protein interactions and oligomerization, most commonly pentamerization[3][6]. The primary functional role of KCTD1—and related family members—involves acting as an adaptor or scaffold, particularly in recruiting substrate proteins for cullin 3 (Cul3) ubiquitin ligase complexes, thereby regulating ubiquitination, proteasomal degradation, and thus cell signaling[1][3]. KCTD1 is essential for neural development and ectodermal/crest cell function, and its mutations can cause congenital malformations such as scalp defects (aplasia cutis)[5][6]. While its precise physiological and pathological mechanisms are still being elucidated, there is currently no evidence that KCTD1 is a direct therapeutic target, nor are there established small-molecule modulators or clinical biomarkers related to its activity[1][6]. Key points: - **Not a classic receptor, enzyme, or channel**—functions as a modulatory scaffold protein via its BTB domain[1][3][6]. - **Regulates protein ubiquitination/degradation** through the cullin 3 ligase complex[1][3]. - **Involved in neurodevelopmental processes** and genetic disorders when mutated[5][6]. - **No known direct-interacting drugs or reported safety concerns**; not currently a drug target. Primary source support: [1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 1 (KCTD1).